Hepatocellular Carcinoma

Key clinical point: The immune checkpoint protein B7-H3 expression correlated positively with androgen receptor expression and was associated with biochemical and clinical recurrence in prostate cancer.

Major finding: Researchers identified B7-H3 positivity in 15% of prostate cancer patients in a Spanish cohort and 38% of patients in a Norwegian cohort. B7-H3 expression was significantly associated with biochemical recurrence in the Spanish cohort (P = .003) and with clinical recurrence in the Norwegian cohort (P = .005).

Study details: The data come from an immunohistochemistry analysis of tissue samples from a total of 327 prostate adenocarcinoma patients who underwent radical prostatectomy; 120 from Spain and 206 from Norway.

Disclosures: The study was funded by the Instituto de Salud Carlos III, the Ministerio de Economía y Competitividad, the Research Council of Norway, Marie Skłodowska-Curie Actions, Radiumhospitalets legater, Norway, and UNIFOR-FRIMED legater, Norway. The researchers had no financial conflicts to disclose.

Source: Nunes-Xavier CE et al. Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.

Key clinical point: The immune checkpoint protein B7-H3 expression correlated positively with androgen receptor expression and was associated with biochemical and clinical recurrence in prostate cancer.

Major finding: Researchers identified B7-H3 positivity in 15% of prostate cancer patients in a Spanish cohort and 38% of patients in a Norwegian cohort. B7-H3 expression was significantly associated with biochemical recurrence in the Spanish cohort (P = .003) and with clinical recurrence in the Norwegian cohort (P = .005).

Study details: The data come from an immunohistochemistry analysis of tissue samples from a total of 327 prostate adenocarcinoma patients who underwent radical prostatectomy; 120 from Spain and 206 from Norway.

Disclosures: The study was funded by the Instituto de Salud Carlos III, the Ministerio de Economía y Competitividad, the Research Council of Norway, Marie Skłodowska-Curie Actions, Radiumhospitalets legater, Norway, and UNIFOR-FRIMED legater, Norway. The researchers had no financial conflicts to disclose.

Source: Nunes-Xavier CE et al. Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.

Key clinical point: The immune checkpoint protein B7-H3 expression correlated positively with androgen receptor expression and was associated with biochemical and clinical recurrence in prostate cancer.

Major finding: Researchers identified B7-H3 positivity in 15% of prostate cancer patients in a Spanish cohort and 38% of patients in a Norwegian cohort. B7-H3 expression was significantly associated with biochemical recurrence in the Spanish cohort (P = .003) and with clinical recurrence in the Norwegian cohort (P = .005).

Study details: The data come from an immunohistochemistry analysis of tissue samples from a total of 327 prostate adenocarcinoma patients who underwent radical prostatectomy; 120 from Spain and 206 from Norway.

Disclosures: The study was funded by the Instituto de Salud Carlos III, the Ministerio de Economía y Competitividad, the Research Council of Norway, Marie Skłodowska-Curie Actions, Radiumhospitalets legater, Norway, and UNIFOR-FRIMED legater, Norway. The researchers had no financial conflicts to disclose.

Source: Nunes-Xavier CE et al. Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.

Key clinical point: At 6 months after robot-assisted radical prostatectomy, functional outcomes, but not postoperative complications, were associated with poor scores on quality-of-life assessments.

Major finding: Functional outcomes of urinary incontinence (UI), erectile dysfunction (ED), and urinary complaints (UC) were not significantly associated with post-operative health-related quality of life, but postoperative complications were significantly associated with a slight increase in UC (P < 0.001).

Study details: The data come from an analysis of 528 prostate cancer patients who underwent robot-assisted radical prostatectomy with or without pelvic node dissection between 2012 and 2020.  Patients completed questionnaires about health-related quality of life and functional outcomes.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hagens MJ et al. J Robotic Surg. 2021 Jun 12. doi: /10.1007/s11701-021-01266-9.

Key clinical point: At 6 months after robot-assisted radical prostatectomy, functional outcomes, but not postoperative complications, were associated with poor scores on quality-of-life assessments.

Major finding: Functional outcomes of urinary incontinence (UI), erectile dysfunction (ED), and urinary complaints (UC) were not significantly associated with post-operative health-related quality of life, but postoperative complications were significantly associated with a slight increase in UC (P < 0.001).

Study details: The data come from an analysis of 528 prostate cancer patients who underwent robot-assisted radical prostatectomy with or without pelvic node dissection between 2012 and 2020.  Patients completed questionnaires about health-related quality of life and functional outcomes.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hagens MJ et al. J Robotic Surg. 2021 Jun 12. doi: /10.1007/s11701-021-01266-9.

Key clinical point: At 6 months after robot-assisted radical prostatectomy, functional outcomes, but not postoperative complications, were associated with poor scores on quality-of-life assessments.

Major finding: Functional outcomes of urinary incontinence (UI), erectile dysfunction (ED), and urinary complaints (UC) were not significantly associated with post-operative health-related quality of life, but postoperative complications were significantly associated with a slight increase in UC (P < 0.001).

Study details: The data come from an analysis of 528 prostate cancer patients who underwent robot-assisted radical prostatectomy with or without pelvic node dissection between 2012 and 2020.  Patients completed questionnaires about health-related quality of life and functional outcomes.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Hagens MJ et al. J Robotic Surg. 2021 Jun 12. doi: /10.1007/s11701-021-01266-9.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: A risk model based on microRNA expression was superior to preoperative prostate specific antigen and clinical Gleason scores for predicting metastasis and prognosis in prostate cancer patients.

Major finding: Prostate cancer patients with higher scores on the PCa-MRS scale showed significantly lower rates of biochemical recurrence-free survival compared to those with lower scores; the area under the curve for the model was 0.925.

Study details: The data come from an evaluation of urine samples from 149 adults with prostate cancer. The researchers examined levels of circulating microRNAs and identified miR-21, miR-16, miR-142-3p, miR-451, and miR-636 as those associated with metastasis.

Disclosures: The study was funded by the National Research Foundation of Korea. The researchers had no financial conflicts to disclose.

Source: Shin S et al. npj Genom Med. 2021 Jun 11. doi: 10.1038/s41525-021-00212-w.

Key clinical point: Gleason scores within grade group 4 prostate cancer were associated with biochemical recurrence, but not cancer-specific mortality or all-cause mortality.

Major finding: Gleason score (GS) 5 + 3 was associated with significantly higher rates of GS upgrading in radical prostatectomy (RP) specimens than either GS 3 + 5 or GS 4 + 4.

Study details: The data come from a retrospective review of 1,791 adults with grade 4 prostate cancer, including 190 with Gleason score (GS) 3 + 5; 1,557 with GS 4 + 4; and 44 with GS 5 + 3).

Disclosures: The study was funded in part by the Medical University of Vienna. The researchers had no financial conflicts to disclose.

Source: Mori K et al. Ann Surg Oncol. 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.

Key clinical point: Gleason scores within grade group 4 prostate cancer were associated with biochemical recurrence, but not cancer-specific mortality or all-cause mortality.

Major finding: Gleason score (GS) 5 + 3 was associated with significantly higher rates of GS upgrading in radical prostatectomy (RP) specimens than either GS 3 + 5 or GS 4 + 4.

Study details: The data come from a retrospective review of 1,791 adults with grade 4 prostate cancer, including 190 with Gleason score (GS) 3 + 5; 1,557 with GS 4 + 4; and 44 with GS 5 + 3).

Disclosures: The study was funded in part by the Medical University of Vienna. The researchers had no financial conflicts to disclose.

Source: Mori K et al. Ann Surg Oncol. 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.

Key clinical point: Gleason scores within grade group 4 prostate cancer were associated with biochemical recurrence, but not cancer-specific mortality or all-cause mortality.

Major finding: Gleason score (GS) 5 + 3 was associated with significantly higher rates of GS upgrading in radical prostatectomy (RP) specimens than either GS 3 + 5 or GS 4 + 4.

Study details: The data come from a retrospective review of 1,791 adults with grade 4 prostate cancer, including 190 with Gleason score (GS) 3 + 5; 1,557 with GS 4 + 4; and 44 with GS 5 + 3).

Disclosures: The study was funded in part by the Medical University of Vienna. The researchers had no financial conflicts to disclose.

Source: Mori K et al. Ann Surg Oncol. 2021 Jun 11. doi: 10.1245/s10434-021-10257-x.

Key clinical point: The Briganti 2019 nomogram accurately predicted lymph node invasion in adults with high-risk, clinically localized prostate cancer.

Major finding: The area under the curve for the Briganti 2019 was 0.71. At a cutoff of 7%, sensitivity, specificity, and negative predictive values were 94.7%, 32.0%a, and 98.8%, respectively.

Study details: The data come from a review of 278 adults with prostate cancer who underwent radical prostatectomy and extended pelvic lymph node dissection. Patients were rated using the Briganti 2019 nomogram; researchers used the area under the curve of the receiver operating characteristic analysis to quantify accuracy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Fukagawa E et al. Int J Clin Oncol. 2021 Jun 12. doi: 10.1007/s10147-021-01954-4. 

Key clinical point: The Briganti 2019 nomogram accurately predicted lymph node invasion in adults with high-risk, clinically localized prostate cancer.

Major finding: The area under the curve for the Briganti 2019 was 0.71. At a cutoff of 7%, sensitivity, specificity, and negative predictive values were 94.7%, 32.0%a, and 98.8%, respectively.

Study details: The data come from a review of 278 adults with prostate cancer who underwent radical prostatectomy and extended pelvic lymph node dissection. Patients were rated using the Briganti 2019 nomogram; researchers used the area under the curve of the receiver operating characteristic analysis to quantify accuracy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Fukagawa E et al. Int J Clin Oncol. 2021 Jun 12. doi: 10.1007/s10147-021-01954-4. 

Key clinical point: The Briganti 2019 nomogram accurately predicted lymph node invasion in adults with high-risk, clinically localized prostate cancer.

Major finding: The area under the curve for the Briganti 2019 was 0.71. At a cutoff of 7%, sensitivity, specificity, and negative predictive values were 94.7%, 32.0%a, and 98.8%, respectively.

Study details: The data come from a review of 278 adults with prostate cancer who underwent radical prostatectomy and extended pelvic lymph node dissection. Patients were rated using the Briganti 2019 nomogram; researchers used the area under the curve of the receiver operating characteristic analysis to quantify accuracy.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.

Source: Fukagawa E et al. Int J Clin Oncol. 2021 Jun 12. doi: 10.1007/s10147-021-01954-4. 

Key clinical point: Hepatocellular carcinoma patients with intermediate or advanced disease experienced significantly improved outcomes when treated with transarterial chemoembolization (TACE) plus sorafenib vs. TACE only.

Major finding: Patients treated with TACE plus sorafenib showed a significant increase in average progression-free survival and overall survival compared to those treated with TACE only (21 months vs. 12 months and 32 months vs. 21 months, respectively).

Study details: The data come from a retrospective review of 85 adults with intermediate or advanced HCC who were treated with transarterial chemoembolization (TACE) alone or with sorafenib.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Zou X et al. Cancer Manag Res. 2021 May 18. doi: 10.2147/CMAR.S304591. 

Key clinical point: Hepatocellular carcinoma patients with intermediate or advanced disease experienced significantly improved outcomes when treated with transarterial chemoembolization (TACE) plus sorafenib vs. TACE only.

Major finding: Patients treated with TACE plus sorafenib showed a significant increase in average progression-free survival and overall survival compared to those treated with TACE only (21 months vs. 12 months and 32 months vs. 21 months, respectively).

Study details: The data come from a retrospective review of 85 adults with intermediate or advanced HCC who were treated with transarterial chemoembolization (TACE) alone or with sorafenib.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Zou X et al. Cancer Manag Res. 2021 May 18. doi: 10.2147/CMAR.S304591. 

Key clinical point: Hepatocellular carcinoma patients with intermediate or advanced disease experienced significantly improved outcomes when treated with transarterial chemoembolization (TACE) plus sorafenib vs. TACE only.

Major finding: Patients treated with TACE plus sorafenib showed a significant increase in average progression-free survival and overall survival compared to those treated with TACE only (21 months vs. 12 months and 32 months vs. 21 months, respectively).

Study details: The data come from a retrospective review of 85 adults with intermediate or advanced HCC who were treated with transarterial chemoembolization (TACE) alone or with sorafenib.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Zou X et al. Cancer Manag Res. 2021 May 18. doi: 10.2147/CMAR.S304591. 

Key clinical point: Preoperative model for end-stage liver disease (MELD) score, post hepatectomy liver failure score (PHLF), and HCC recurrence were independent predictors of survival for HCC patients with cirrhosis who underwent curative liver resection.

Major finding: The preoperative MELD score and grades A, B, or C of the post hepatectomy liver failure score (PHLF) were significant independent predictors for survival in HCC patients with cirrhosis who underwent curative liver resection, with hazard ratios of 1.37 (MELD), 2.33 (grade A), 3.15 (grade B), 373.41 (grade C). HCC recurrence also was a significant independent predictor of survival (HA 11.67).

Study details: The data come from a review of 120 adults with HCC with cirrhosis who underwent curative resection.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Elshaarawy O et al. World J Gastrointest Oncol. 2021 May 15. doi: 10.4251/wjgo.v13.i5.424.

Key clinical point: Preoperative model for end-stage liver disease (MELD) score, post hepatectomy liver failure score (PHLF), and HCC recurrence were independent predictors of survival for HCC patients with cirrhosis who underwent curative liver resection.

Major finding: The preoperative MELD score and grades A, B, or C of the post hepatectomy liver failure score (PHLF) were significant independent predictors for survival in HCC patients with cirrhosis who underwent curative liver resection, with hazard ratios of 1.37 (MELD), 2.33 (grade A), 3.15 (grade B), 373.41 (grade C). HCC recurrence also was a significant independent predictor of survival (HA 11.67).

Study details: The data come from a review of 120 adults with HCC with cirrhosis who underwent curative resection.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Elshaarawy O et al. World J Gastrointest Oncol. 2021 May 15. doi: 10.4251/wjgo.v13.i5.424.

Key clinical point: Preoperative model for end-stage liver disease (MELD) score, post hepatectomy liver failure score (PHLF), and HCC recurrence were independent predictors of survival for HCC patients with cirrhosis who underwent curative liver resection.

Major finding: The preoperative MELD score and grades A, B, or C of the post hepatectomy liver failure score (PHLF) were significant independent predictors for survival in HCC patients with cirrhosis who underwent curative liver resection, with hazard ratios of 1.37 (MELD), 2.33 (grade A), 3.15 (grade B), 373.41 (grade C). HCC recurrence also was a significant independent predictor of survival (HA 11.67).

Study details: The data come from a review of 120 adults with HCC with cirrhosis who underwent curative resection.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.  

Source: Elshaarawy O et al. World J Gastrointest Oncol. 2021 May 15. doi: 10.4251/wjgo.v13.i5.424.

Key clinical point: Hepatocellular carcinoma patients with lung or bone metastasis have a significantly worse prognosis than patients without these metastases.  

Major finding: In a multivariate analysis, independent predictors of poor overall survival and cancer-specific survival in HCC patients included age 52 years and older, male sex, low degree of tumor differentiation, N1 stage, lack of primary surgery or chemoradiotherapy, tumor size greater than 6 cm, and multiple organ metastasis.

Study details: The data come from a retrospective review of 3,126 adults with distant metastasis of hepatocellular carcinoma from 2010 to 2015; patients were grouped based on metastatic sites.

Disclosures: The study was funded by the Natural Science Foundation of Jiangsu Province. The researchers had no financial conflicts to disclose.  

Source: Zhan H et al. Front Oncol. 2021 May 10. doi: 10.3389/fonc.2021.652768.

Key clinical point: Hepatocellular carcinoma patients with lung or bone metastasis have a significantly worse prognosis than patients without these metastases.  

Major finding: In a multivariate analysis, independent predictors of poor overall survival and cancer-specific survival in HCC patients included age 52 years and older, male sex, low degree of tumor differentiation, N1 stage, lack of primary surgery or chemoradiotherapy, tumor size greater than 6 cm, and multiple organ metastasis.

Study details: The data come from a retrospective review of 3,126 adults with distant metastasis of hepatocellular carcinoma from 2010 to 2015; patients were grouped based on metastatic sites.

Disclosures: The study was funded by the Natural Science Foundation of Jiangsu Province. The researchers had no financial conflicts to disclose.  

Source: Zhan H et al. Front Oncol. 2021 May 10. doi: 10.3389/fonc.2021.652768.

Key clinical point: Hepatocellular carcinoma patients with lung or bone metastasis have a significantly worse prognosis than patients without these metastases.  

Major finding: In a multivariate analysis, independent predictors of poor overall survival and cancer-specific survival in HCC patients included age 52 years and older, male sex, low degree of tumor differentiation, N1 stage, lack of primary surgery or chemoradiotherapy, tumor size greater than 6 cm, and multiple organ metastasis.

Study details: The data come from a retrospective review of 3,126 adults with distant metastasis of hepatocellular carcinoma from 2010 to 2015; patients were grouped based on metastatic sites.

Disclosures: The study was funded by the Natural Science Foundation of Jiangsu Province. The researchers had no financial conflicts to disclose.  

Source: Zhan H et al. Front Oncol. 2021 May 10. doi: 10.3389/fonc.2021.652768.

Key clinical point: Arterial input function and quality were similar for HCC patients who received either gadoxetate disodium or gadobenate dimeglumine during the first 3 minutes after contrast injection during DCE-MRI. 

Major finding: Measures of arterial input function quality, modelled, and model-free perfusion parameters were not significantly different for patients who received either gadoxetate disodium or gadobenate dimeglumine during the first 3 minutes after contrast injection during DCE-MRI; P values ranged from 0.054-0.932. However, patients in the gadoxetate disodium group showed significantly lower liver parenchymal flow and later liver enhancement (P < 0.001).

Study details: The data come from a prospective study of 66 adults with 83 hepatocellular carcinomas who underwent dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI).

Disclosures: The study was supported in part by the National Institutes of Health. The researchers had no financial conflicts to disclose.  

Source: Stocker D et al. Eur Radiol. 2021 May 27. doi: 10.1007/s00330-021-08068-5.

Key clinical point: Arterial input function and quality were similar for HCC patients who received either gadoxetate disodium or gadobenate dimeglumine during the first 3 minutes after contrast injection during DCE-MRI. 

Major finding: Measures of arterial input function quality, modelled, and model-free perfusion parameters were not significantly different for patients who received either gadoxetate disodium or gadobenate dimeglumine during the first 3 minutes after contrast injection during DCE-MRI; P values ranged from 0.054-0.932. However, patients in the gadoxetate disodium group showed significantly lower liver parenchymal flow and later liver enhancement (P < 0.001).

Study details: The data come from a prospective study of 66 adults with 83 hepatocellular carcinomas who underwent dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI).

Disclosures: The study was supported in part by the National Institutes of Health. The researchers had no financial conflicts to disclose.  

Source: Stocker D et al. Eur Radiol. 2021 May 27. doi: 10.1007/s00330-021-08068-5.

Key clinical point: Arterial input function and quality were similar for HCC patients who received either gadoxetate disodium or gadobenate dimeglumine during the first 3 minutes after contrast injection during DCE-MRI. 

Major finding: Measures of arterial input function quality, modelled, and model-free perfusion parameters were not significantly different for patients who received either gadoxetate disodium or gadobenate dimeglumine during the first 3 minutes after contrast injection during DCE-MRI; P values ranged from 0.054-0.932. However, patients in the gadoxetate disodium group showed significantly lower liver parenchymal flow and later liver enhancement (P < 0.001).

Study details: The data come from a prospective study of 66 adults with 83 hepatocellular carcinomas who underwent dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI).

Disclosures: The study was supported in part by the National Institutes of Health. The researchers had no financial conflicts to disclose.  

Source: Stocker D et al. Eur Radiol. 2021 May 27. doi: 10.1007/s00330-021-08068-5.